Abhay Singh, PhD

Abhay Singh, PhD

Assistant Professor of Radiation Oncology


  • BS, Chemistry: BRABU (Muzaffarpur, India) (2002)
  • MS, Biochemistry: Jamia Hamdard (New Delhi, India) (2005)
  • PhD, Biophysics, Cancer Biology: All India Institute of Medical Sciences (New Delhi, India) (2012)


Dr. Abhay Singh stands at the forefront of antibody discovery and development, wielding a profound expertise cultivated through a comprehensive background in biochemistry, immunology, and molecular biology. His unwavering commitment to advancing transformative cancer therapeutic solutions has defined a distinguished career marked by notable contributions. Dr. Singh’s versatility is evident in his adept handling of various antibody formats, from traditional monoclonal antibodies (mAbs) to polyclonal antibodies, where he has optimized production processes for scalability and efficiency. Pioneering cutting-edge techniques, Dr. Singh designs novel antibody libraries and implements comprehensive screening strategies, ensuring meticulous identification of antibodies that meet the highest standards for further development. Beyond conventional formats, his groundbreaking work extends to engineered antibody formats, notably bispecific antibodies, unlocking new dimensions for precision medicine. Dr. Singh’s impactful contributions also span the realm of antibody-drug conjugates (ADCs) and radioimmunoconjugates, showcasing a commitment to innovative drug delivery strategies that maximize therapeutic impact while minimizing side effects. His leadership extends beyond the laboratory, actively collaborating with industry and academic partners, successfully progressing antibody candidates from the laboratory to clinical trials. Dr. Singh’s influence resonates globally as a sought-after speaker at international conferences and a prolific author contributing to high-impact journals, underscoring his dedication to advancing healthcare through innovative and targeted therapeutic strategies.


View full list

Related Links

Research Profile